Recent News

• 02.08.2026 - TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
• 02.06.2026 - TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
• 01.27.2026 - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
• 01.13.2026 - TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
• 01.07.2026 - TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
• 11.28.2025 - TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
• 11.19.2025 - TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
• 11.10.2025 - TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
• 11.03.2025 - TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Recent Filings

• 01.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2026 - EX-99.1 EX-99.1
• 01.13.2026 - 8-K Current report
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - 144 Report of proposed sale of securities
• 11.10.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]